Literature DB >> 26989862

Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism.

Ann-Marie Meredith1, Crispin R Dass1,2.   

Abstract

OBJECTIVES: The use of doxorubicin, a drug utilised for many years to treat a wide variety of cancers, has long been limited due to the significant toxicity that can occur not only during, but also years after treatment. It has multiple mechanisms of action including the intercalation of DNA, inhibition of topoisomerase II and the production of free radicals. We review the literature, with the aim of highlighting the role of drug concentration being an important determinant on the unfolding cell biological events that lead to cell stasis or death.
METHODS: The PubMed database was consulted to compile this review. KEY
FINDINGS: It has been found that the various mechanisms of action at the disposal of doxorubicin culminate in either cell death or cell growth arrest through various cell biological events, such as apoptosis, autophagy, senescence and necrosis. Which of these events is the eventual cause of cell death or growth arrest appears to vary depending on factors such as the patient, cell and cancer type, doxorubicin concentration and the duration of treatment.
CONCLUSIONS: Further understanding of doxorubicin's influence on cell biological events could lead to an improvement in the drug's efficacy and reduce toxicity.
© 2016 Royal Pharmaceutical Society.

Entities:  

Keywords:  autophagy; cancer; doxorubicin; metabolism; mitochondria

Mesh:

Substances:

Year:  2016        PMID: 26989862     DOI: 10.1111/jphp.12539

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  56 in total

1.  From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis.

Authors:  Aikaterini F Giannopoulou; Athanassios D Velentzas; Athanasios K Anagnostopoulos; Adamantia Agalou; Nikos C Papandreou; Stamatia A Katarachia; Dimitra G Koumoundourou; Eumorphia G Konstantakou; Vasiliki I Pantazopoulou; Anastasios Delis; Maria T Michailidi; Dimitrios Valakos; Dimitris Chatzopoulos; Popi Syntichaki; Vassiliki A Iconomidou; Ourania E Tsitsilonis; Issidora S Papassideri; Gerassimos E Voutsinas; Polydefkis Hatzopoulos; Dimitris Thanos; Dimitris Beis; Ema Anastasiadou; George Th Tsangaris; Dimitrios J Stravopodis
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

Review 2.  Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications.

Authors:  Jacek Zielonka; Joy Joseph; Adam Sikora; Micael Hardy; Olivier Ouari; Jeannette Vasquez-Vivar; Gang Cheng; Marcos Lopez; Balaraman Kalyanaraman
Journal:  Chem Rev       Date:  2017-06-27       Impact factor: 60.622

Review 3.  Doxorubicin-induced chronic dilated cardiomyopathy-the apoptosis hypothesis revisited.

Authors:  Cynthia Kankeu; Kylie Clarke; Egle Passante; Heinrich J Huber
Journal:  J Mol Med (Berl)       Date:  2016-12-08       Impact factor: 4.599

Review 4.  Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells.

Authors:  Rachel E Nicoletto; Clyde M Ofner
Journal:  Cancer Chemother Pharmacol       Date:  2022-02-12       Impact factor: 3.333

5.  Using mathematical modeling to estimate time-independent cancer chemotherapy efficacy parameters.

Authors:  Christine Pho; Madison Frieler; Giri R Akkaraju; Anton V Naumov; Hana M Dobrovolny
Journal:  In Silico Pharmacol       Date:  2021-12-05

6.  Soursop leaves (Annona muricata L.) endophytic fungi anticancer activity against HeLa cells.

Authors:  Akhmad Endang Zainal Hasan; Heddy Julistiono; Nurliani Bermawie; Eny Ida Riyanti; Fahru Reza Arifni
Journal:  Saudi J Biol Sci       Date:  2022-06-21       Impact factor: 4.052

7.  Target-specific delivery of doxorubicin to human glioblastoma cell line via ssDNA aptamer.

Authors:  Abdullah Tahir Bayrac; Oya Ercan Akca; Fusun Inci Eyidogan; Huseyin Avni Oktem
Journal:  J Biosci       Date:  2018-03       Impact factor: 1.826

8.  GlucoCEST MRI for the Evaluation Response to Chemotherapeutic and Metabolic Treatments in a Murine Triple-Negative Breast Cancer: A Comparison with[18F]F-FDG-PET.

Authors:  Martina Capozza; Annasofia Anemone; Chetan Dhakan; Melania Della Peruta; Martina Bracesco; Sara Zullino; Daisy Villano; Enzo Terreno; Dario Livio Longo; Silvio Aime
Journal:  Mol Imaging Biol       Date:  2021-08-12       Impact factor: 3.488

9.  Differential sensitivity of renal carcinoma cells to doxorubicin and epigenetic therapeutics depends on the genetic background.

Authors:  Narayan Acharya; Kamaleshwar P Singh
Journal:  Mol Cell Biochem       Date:  2021-02-16       Impact factor: 3.396

Review 10.  Breast cancer: Muscarinic receptors as new targets for tumor therapy.

Authors:  Alejandro Español; Agustina Salem; Yamila Sanchez; María Elena Sales
Journal:  World J Clin Oncol       Date:  2021-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.